Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2023-10-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民集团关于公司会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in the company's accounting policies, referencing new accounting standards issued by the Ministry of Finance and their impact on the company's financial statements. It includes details about the policy changes, their effects, and approvals from the audit committee, board of directors, independent directors, and supervisory board. The document does not contain full financial statements or comprehensive financial performance data but rather informs stakeholders about the accounting policy change and its implications. It is not a full annual or interim report, nor is it a certification or a brief announcement of a report publication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2023-10-20 Chinese
健民集团关于召开2023年第3季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2023 third quarter earnings explanation meeting (业绩说明会) for investors. It specifies the date, time, location, and participation method for the meeting, which is an interactive online session to discuss the company's Q3 financial results. The document does not contain actual financial data or detailed financial statements but serves to inform investors about the upcoming event where such information will be discussed. The document length is short (1485 characters) and it is clearly an announcement rather than the report or transcript itself. Therefore, it fits the category of an Investor Presentation (IP) announcement or a Call Transcript (CT) announcement. However, since it is about an earnings explanation meeting (业绩说明会), which is typically a form of investor presentation focusing on financials and strategy, the best classification is Investor Presentation (IP).
2023-10-20 Chinese
健民集团独立董事关于公司会计政策变更的独立意见
Audit Report / Information Classification · 90% confidence The document is an independent opinion from the independent directors regarding a change in the company's accounting policies. It references compliance with accounting standards and regulatory requirements but does not contain financial statements or detailed financial data. It is a formal opinion related to governance and regulatory compliance rather than a full audit report or annual report. Therefore, it fits best under Audit Report / Information (AR), which includes applied accounting principles and related independent opinions. Q3 2023
2023-10-20 Chinese
健民集团第十届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 16th meeting of the 10th Board of Directors of the company. It includes voting results on the approval of the company's 2023 Q3 report and a change in accounting policy. The document references the 2023 Q3 report and a separate announcement about accounting policy changes, directing readers to external sources for the full reports. The document itself does not contain the full quarterly report or detailed financial data, but rather announces the board's decisions and voting outcomes. This fits the category of Board/Management Information (MANG), as it relates to board meeting resolutions and decisions. The document length is short (803 characters), and it is not the full quarterly report (IR) but an announcement of board resolutions including approval of the report. Therefore, the correct classification is MANG with high confidence.
2023-10-20 Chinese
健民集团2023年第3季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年第三季度报告' which translates to '2023 Third Quarter Report'. It contains detailed financial data including income statements, balance sheets, cash flow statements, and notes about accounting policy changes. The report covers a period shorter than a full fiscal year (the third quarter), and includes unaudited financial statements and management assurances about the accuracy of the report. This matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data, not just an announcement or certification. Therefore, the correct classification is IR (Interim / Quarterly Report). 9M 2023
2023-10-20 Chinese
健民集团2023年前三季度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2023 年前三季度业绩快报公告" which translates to "2023 First Three Quarters Performance Express Announcement." It contains preliminary financial data for the first nine months of 2023, including revenue, profit, and earnings per share, but explicitly states that the data is preliminary and unaudited, and that the final detailed data will be disclosed in the company's regular report. The document is relatively short (1495 characters) and serves as a quick earnings update rather than a full interim or quarterly report with comprehensive financial statements and analysis. Therefore, it fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. 9M 2023
2023-10-16 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.